Payment overview · 2025
General Payments
$144.74
3 reported records · 3 companies
Healthcare provider profile · identity verified
Deirdre Arroyo, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DANVILLE, VA · NPI 1144677246
Verified facts
What the public records show
CMS Open Payments records show Deirdre Arroyo, NP received $144.74 in general payments during 2025 across 3 reported records.
AstraZeneca Pharmaceuticals LP accounted for 78.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $112.94 | 78.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.60 | 12.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.20 | 9.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $144.74 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $112.94 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
42 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
22 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 773 | 178 |
| Amlodipine Besylate | Amlodipine Besylate | 624 | 141 |
| Losartan Potassium | Losartan Potassium | 440 | 103 |
| Omeprazole | Omeprazole | 342 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 314 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 254 | 74 |
| Metformin Hcl | Metformin Hcl | 244 | 60 |
| Carvedilol | Carvedilol | 241 | 55 |
| Jardiance | Empagliflozin | 213 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 51 |
| Lisinopril | Lisinopril | 185 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 174 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 171 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 152 | 42 |
| Glipizide | Glipizide | 144 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 140 | 32 |
| Montelukast Sodium | Montelukast Sodium | 138 | 35 |
| Buspirone Hcl | Buspirone Hcl | 136 | 30 |
| Potassium Chloride | Potassium Chloride | 126 | 29 |
| Trulicity | Dulaglutide | 124 | 26 |
| Gabapentin | Gabapentin | 121 | 37 |
| Furosemide | Furosemide | 119 | 40 |
| Topiramate | Topiramate | 115 | 30 |
| Ezetimibe | Ezetimibe | 114 | 21 |
| Glipizide Er | Glipizide | 105 | 26 |
| Sertraline Hcl | Sertraline Hcl | 102 | 24 |
| Meloxicam | Meloxicam | 101 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 21 |
| Tramadol Hcl | Tramadol Hcl | 97 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 93 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 21 |
| Allopurinol | Allopurinol | 87 | 21 |
| Prednisone | Prednisone | 86 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 77 | 14 |
| Trazodone Hcl | Trazodone Hcl | 77 | 21 |
| Chlorthalidone | Chlorthalidone | 76 | 22 |
| Simvastatin | Simvastatin | 76 | 20 |
| Famotidine | Famotidine | 75 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 38 |
| Farxiga | Dapagliflozin Propanediol | 74 | 15 |
| Linzess | Linaclotide | 74 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 71 | 18 |
| Eliquis | Apixaban | 71 | 18 |
| Ibuprofen | Ibuprofen | 71 | 23 |
| Mirtazapine | Mirtazapine | 69 | 21 |
| Unithroid | Levothyroxine Sodium | 68 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 62 | 16 |
| Valsartan | Valsartan | 62 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 56 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | 16 |
| Ozempic | Semaglutide | 53 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 15 |
| Atenolol | Atenolol | 47 | suppressed |
| Naproxen | Naproxen | 47 | 13 |
| Meclizine Hcl | Meclizine Hcl | 44 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 23 |
| Ondansetron Odt | Ondansetron | 43 | 16 |
| Baclofen | Baclofen | 42 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | 16 |
| Lidocaine | Lidocaine | 40 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 34 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | 15 |
| Promethazine Hcl | Promethazine Hcl | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | 12 |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 14 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 35 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 24 |
| Telmisartan | Telmisartan | 30 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 21 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Azithromycin | Azithromycin | 26 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 25 | 15 |
| Celecoxib | Celecoxib | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 19 |
| Trueplus Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $144.74 · 3 records | AstraZeneca Pharmaceuticals LP | BREZTRI, Ozempic, Rybelsus, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error